The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways

Cancer Letters

Volumn 288, Issue 2, 2010, Pages 170-176

  Peverelli, Erika ^a   Olgiati, Luca ^a   Locatelli, Marco ^a   Magni, Paolo ^b   Fustini, Marco Faustini ^c   Frank, Giorgio ^c   Mantovani, Giovanna ^a   Beck Peccoz, Paolo ^a   Spada, Anna ^a   Lania, Andrea ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Center for Endocrinological Oncology   (Italy)

^c BELLARIA HOSPITAL   (Italy)

Author keywords

Apoptosis; Cell proliferation; Chimera; Dopamine receptor; Pituitary adenoma; Somatostatin receptor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ANTINEOPLASTIC AGENT; BIM 23120; BIM 23206; BIM 23A 760; BIM 53097; CASPASE 3; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PASIREOTIDE; PROTEIN P27; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; NONFUNCTIONING PITUITARY ADENOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL PROLIFERATION; DOPAMINE; DOPAMINE AGONISTS; ENZYME ACTIVATION; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PITUITARY NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTORS, DOPAMINE D2; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TUMOR CELLS, CULTURED;

EID: 74849085773     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.06.034     Document Type: Article

References (31)

1. Losa M., Mortini P., Barzaghi R., Ribotto P., Terreni M.R., Marzoli S.B., Pieralli S., and Giovanelli M. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J. Neurosurg. 108 (2008) 525-532
2. Ferrante E., Ferraroni M., Castrignanò T., Menicatti L., Anagni M., Reimondo G., Del Monte P., Bernasconi D., Loli P., Faustini-Fustini M., Borretta G., Terzolo M., Losa M., Morabito A., Spada A., Beck-Peccoz P., and Lania A.G. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur. J. Endocrinol. 155 (2006) 823-829
3. Greenman Y., Ouaknine G., Veshchev I., Reider-Groswasser I.I., Segev Y., and Stern N. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clin. Endocrinol. 58 (2003) 763-769
4. Neto L.V., Machado E.D., Luque R.M., Taboada G.F., Marcondes J.B., Chimelli L.M., Quintella L.P., Niemeyer P., de Carvalho D.P., Kineman R.D., and Gadelha M.R. Expression analysis of dopamine receptor subtypes in normal human pituitaries, non-functioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J. Clin. Endocrinol. Metab. 94 (2009) 1931-1937
5. Renner U., Arzberger T., Pagotto U., Leimgruber S., Uhl E., Müller A., Lange M., Weindl A., and Stalla G.K. Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically non-functioning pituitary adenomas. J. Clin. Endocrinol. Metab. 83 (1998) 1368-1375
6. Taboada G.F., Luque R.M., Bastos W., Guimarães R.F., Marcondes J.B., Chimelli L.M., Fontes R., Mata P.J., Filho P.N., Carvalho D.P., Kineman R.D., and Gadelha M.R. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur. J. Endocrinol. 156 (2007) 65-74
7. Pivonello R., Ferone D., de Herder W.W., de Krijger R.R., Waaijers M., Mooij D.M., van Koetsveld P.M., Barreca A., De Caro M.L., Lombardi G., Colao A., Lamberts S.W., and Hofland L.J. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J. Clin. Endocrinol. Metab. 89 (2004) 4493-4502
8. Bevan J.S., Webster J., Burke C.W., and Scanlon M.F. Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev. 13 (1992) 220-240
9. Colao A., Ferone D., Lastoria S., Cerbone G., Di Sarno A., Di Somma C., Lucci R., and Lombardi G. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Clin. Endocrinol. 52 (2000) 437-445
10. de Bruin T.W., Kwekkeboom D.J., Van't Verlaat J.W., Reubi J.C., Krenning E.P., Lamberts S.W., and Croughs R.J. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J. Clin. Endocrinol. Metab. 75 (1992) 310-1317
11. Colao A., Di Somma C., Pivonello R., Faggiano A., Lombardi G., and Savastano S. Medical therapy for clinically non-functioning pituitary adenomas. Endocr. Relat. Cancer 15 (2008) 905-915
12. Renner U., Mojto J., Lange M., Müller O.A., von Werder K., and Stalla G.K. Effect of bromocriptine and SMS 201-995 on growth of human somatotrophic and non-functioning pituitary adenoma cells in vitro. Eur. J. Endocrinol. 130 (1994) 80-91
13. Greenman Y., Tordjman K., Osher E., Veshchev I., Shenkerman G., Reider-Groswasser I.I., Segev Y., Ouaknine G., and Stern N. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin. Endocrinol. 63 (2005) 39-44
14. Jaquet P., Gunz G., Saveanu A., Dufour H., Taylor J., Dong J., Kim S., Moreau J.P., Enjalbert A., and Culler M.D. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur. J. Endocrinol. 153 (2005) 135-141
15. Saveanu A., Gunz G., Guillen S., Dufour H., Culler M.D., and Jaquet P. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 83 (2006) 258-263
16. Fusco A., Gunz G., Jaquet P., Dufour H., Germanetti A.L., Culler M.D., Barlier A., and Saveanu A. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur. J. Endocrinol. 158 (2008) 595-603
17. Florio T., Barbieri F., Spaziante R., Zona G., Hofland L., van Koetsveld P.M., Feelders R.A., Stalla G.K., Theodoropoulou M., Culler M.D., Dong J., Taylor J.E., Moreau J.P., Saveanu A., Gunz G., Dufour H., and Jaquet P. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr. Relat. Cancer. 15 (2008) 583-596
18. Gruszka A., Kunert-Radek J., Radek A., Pisarek H., Taylor J., Dong J.Z., Culler M.D., and Pawlikowski M. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro. Life Sci. 78 (2006) 689-693
19. 2+ levels and adenylyl cyclase activity in human nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 73 (1991) 913-918
20. Florio T., Thellung S., Arena S., Corsaro A., Spaziante R., Gussoni G., Acuto G., Giusti M., Giordano G., and Schettini G. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur. J. Endocrinol. 141 (1999) 396-408
21. Florio T., Thellung S., Corsaro A., Bocca L., Arena S., Pattarozzi A., Villa V., Massa A., Diana F., Schettini D., Barbieri F., Ravetti J.L., Spaziante R., Giusti M., and Schettini G. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin. Endocrinol. 59 (2003) 115-128
22. Ferrante E., Pellegrini C., Bondioni S., Peverelli E., Locatelli M., Gelmini P., Luciani P., Peri A., Mantovani G., Bosari S., Beck-Peccoz P., Spada A., and Lania A. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr. Relat. Cancer. 13 (2006) 955-962
23. Candolfi M., Zaldivar V., De Laurentiis A., Jaita G., Pisera D., and Seilicovich A. TNF-α induces apoptosis of lactotropes from female rats. Endocrinology 143 (2002) 3611-3617
24. Lania A.G., Mantovani G., Ferrero S., Pellegrini C., Bondioni S., Peverelli E., Braidotti P., Locatelli M., Zavanone M.L., Ferrante E., Bosari S., Beck-Peccoz P., and Spada A. Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase A regulatory subunit 1A protein. Cancer Res. 64 (2004) 9193-9198
25. Corbetta S., Eller-Vainicher C., Vicentini L., Lania A., Mantovani G., Beck-Peccoz P., and Spada A. Modulation of cyclin D1 expression in human tumoral parathyroid cells: effects of growth factors and calcium sensing receptor activation. Cancer Lett. 255 (2007) 34-41
26. Boatright K.M., and Salvesen G.S. Mechanisms of caspase activation. Curr. Opin. Cell Biol. 15 (2003) 725-731
27. Luciani P., Gelmini S., Ferrante E., Lania A., Benvenuti S., Baglioni S., Mantovani G., Cellai I., Ammannati F., Spada A., Serio M., and Peri A. Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 90 (2005) 6156-6161
28. Iaccarino C., Samad T.A., Mathis C., Kercret H., Picetti R., and Borrelli E. Control of lactotrop proliferation by dopamine: essential role of signalling through D2 receptors and ERKs. Proc. Natl. Acad. Sci. USA 99 (2002) 14530-14535
29. An J.J., Cho S.R., Jeong D.W., Park K.W., Ahn Y.S., and Baik J.H. Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol. Cell. Endocrinol. 206 (2003) 49-62
30. Kanasaki H., Fukunaga K., Takahashi K., Miyazaki K., and Miyamoto E. Involvement of p38 mitogen-activated protein kinase activation in bromocriptine-induced apoptosis in rat pituitary GH3 cells. Biol. Reprod. 62 (2000) 1486-1494
31. Kidd M., Drozdov I., Joseph R., Pfragner R., Culler M., and Modlin I. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 113 (2008) 690-700